Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X.

Int J Cancer. 2019 Aug 24. doi: 10.1002/ijc.32638. [Epub ahead of print]

PMID:
31444972
2.

The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.

Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA.

Mol Cancer Res. 2019 Aug 8. doi: 10.1158/1541-7786.MCR-18-0605. [Epub ahead of print]

PMID:
31395667
3.

Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer.

Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Ingebriktsen LM, Fassina A, Taskén KA, Mills IG, Donnem T, Bremnes RM, Busund LT.

Sci Rep. 2019 Jul 23;9(1):10662. doi: 10.1038/s41598-019-47234-0.

4.

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T.

Clin Exp Immunol. 2019 Jul;197(1):74-82. doi: 10.1111/cei.13283. Epub 2019 Mar 21.

5.

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.

Berg J, Halvorsen AR, Bengtson MB, Taskén KA, Mælandsmo GM, Yndestad A, Halvorsen B, Brustugun OT, Aukrust P, Ueland T, Helland Å.

BMC Cancer. 2018 Jul 13;18(1):739. doi: 10.1186/s12885-018-4659-0.

6.

Role of serum response factor expression in prostate cancer biochemical recurrence.

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW.

Prostate. 2018 Jul;78(10):724-730. doi: 10.1002/pros.23516. Epub 2018 Apr 2.

PMID:
29608018
7.

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB.

Br J Cancer. 2018 Mar 20;118(6):e11. doi: 10.1038/bjc.2017.470. Epub 2018 Feb 20.

8.

Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB.

Br J Cancer. 2017 Nov 21;117(11):1656-1664. doi: 10.1038/bjc.2017.346. Epub 2017 Oct 3. Erratum in: Br J Cancer. 2018 Feb 20;:.

9.

Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness.

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS.

Urol Oncol. 2017 Mar;35(3):111.e1-111.e8. doi: 10.1016/j.urolonc.2016.10.002. Epub 2016 Nov 9.

PMID:
27838142
10.

Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA.

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R.

Clin Nutr. 2017 Jun;36(3):672-679. doi: 10.1016/j.clnu.2016.06.014. Epub 2016 Jun 30.

11.

PBX3 is a putative biomarker of aggressive prostate cancer.

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA.

Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25.

12.

Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA.

Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479.

13.

β-Adrenergic Receptor Signaling in Prostate Cancer.

Braadland PR, Ramberg H, Grytli HH, Taskén KA.

Front Oncol. 2015 Jan 12;4:375. doi: 10.3389/fonc.2014.00375. eCollection 2014. Review.

15.

TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells.

Eide T, Ramberg H, Glackin C, Tindall D, Taskén KA.

Cancer Cell Int. 2013 Jan 31;13(1):4. doi: 10.1186/1475-2867-13-4.

16.

Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA.

Eur Urol. 2014 Mar;65(3):635-41. doi: 10.1016/j.eururo.2013.01.007. Epub 2013 Jan 14.

PMID:
23351721
17.

Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL.

Prostate. 2013 Feb 15;73(3):250-60. doi: 10.1002/pros.22564. Epub 2012 Jul 20.

PMID:
22821802
18.

The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy.

Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A.

Br J Nutr. 2012 Dec 28;108(12):2138-47. doi: 10.1017/S0007114512000384. Epub 2012 Mar 8.

PMID:
22397815
19.

Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial.

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ.

Nutr Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. Epub 2011 Jun 29.

PMID:
21714686
20.

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA.

Mol Cancer. 2011 May 6;10:50. doi: 10.1186/1476-4598-10-50.

21.

The star chart to Ta bladder cancer: an unsophisticated analysis of two-dimensional gel electrophoresis proteome maps.

Røtterud R, Malmström PU, Wahlqvist R, Taskén KA.

Scand J Urol Nephrol. 2010 Mar;44(2):76-83. doi: 10.3109/00365590903510729.

PMID:
20059407
22.

Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.

Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.

PMID:
18454446
23.

Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.

Kvissel AK, Ramberg H, Eide T, Svindland A, Skålhegg BS, Taskén KA.

Cell Signal. 2007 Feb;19(2):401-9. Epub 2006 Jul 25.

PMID:
16949795
24.

[Markers for diagnosis, prediction and prognosis of prostate cancer].

Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S.

Tidsskr Nor Laegeforen. 2005 Dec 1;125(23):3279-82. Norwegian.

25.

Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines.

Dizeyi N, Bjartell A, Hedlund P, Taskén KA, Gadaleanu V, Abrahamsson PA.

Eur Urol. 2005 Jun;47(6):895-900. Epub 2005 Mar 3.

PMID:
15925089
26.

Protein kinase A-anchoring protein AKAP95 interacts with MCM2, a regulator of DNA replication.

Eide T, Taskén KA, Carlson C, Williams G, Jahnsen T, Taskén K, Collas P.

J Biol Chem. 2003 Jul 18;278(29):26750-6. Epub 2003 May 9.

27.

USF2 inhibits C/EBP-mediated transcriptional regulation of the RIIbeta subunit of cAMP-dependent protein kinase.

Dahle MK, Taskén K, Taskén KA.

BMC Mol Biol. 2002 Jun 21;3:10. Epub 2002 Jun 21.

28.

Distinct but overlapping domains of AKAP95 are implicated in chromosome condensation and condensin targeting.

Eide T, Carlson C, Taskén KA, Hirano T, Taskén K, Collas P.

EMBO Rep. 2002 May;3(5):426-32. Epub 2002 Apr 18.

29.

Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP.

Dahle MK, Grønning LM, Cederberg A, Blomhoff HK, Miura N, Enerbäck S, Taskén KA, Taskén K.

J Biol Chem. 2002 Jun 21;277(25):22902-8. Epub 2002 Apr 9.

30.

Cyclic AMP regulates expression of the RI alpha subunit of cAMP-dependent protein kinase through an alternatively spliced 5' UTR.

Dahle MK, Knutsen HK, Taskén KA, Pilz R, Taskén K.

Eur J Biochem. 2001 Nov;268(22):5920-9.

31.

Novel alternatively spliced mRNA (1c) of the protein kinase A RIα subunit is implicated in haploid germ cell specific expression.

Dahle MK, Reinton N, Orstavik S, Taskén KA, Taskén K.

Mol Reprod Dev. 2001 May;59(1):11-6.

PMID:
11335941
32.

Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area.

Taskén KA, Collas P, Kemmner WA, Witczak O, Conti M, Taskén K.

J Biol Chem. 2001 Jun 22;276(25):21999-2002. Epub 2001 Apr 2.

33.
34.
35.

Calcium/phospholipid-dependent protein kinases in rat Sertoli cells: regulation of androgen receptor messenger ribonucleic acid.

Ree AH, Hansson V, Walaas SI, Eskild W, Taskén KA.

Biol Reprod. 1999 May;60(5):1257-62.

PMID:
10208993
36.

Isoform-specific regulation of the CCAAT/enhancer-binding protein family of transcription factors by 3',5'-cyclic adenosine monophosphate in Sertoli cells.

Grønning LM, Dahle MK, Taskén KA, Enerbäck S, Hedin L, Taskén K, Knutsen HK.

Endocrinology. 1999 Feb;140(2):835-43.

PMID:
9927313
37.

Characterization of the 5'-flanking region of the gene for the cAMP-inducible protein kinase A subunit, RIIbeta, in Sertoli cells.

Knutsen HK, Taskén K, Eskild W, Richards JS, Kurten RC, Torjesen PA, Jahnsen T, Hansson V, Guérin S, Taskén KA.

Mol Cell Endocrinol. 1997 Apr 25;129(1):101-14.

PMID:
9175634
38.

Structure, function, and regulation of human cAMP-dependent protein kinases.

Taskén K, Skålhegg BS, Taskén KA, Solberg R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T.

Adv Second Messenger Phosphoprotein Res. 1997;31:191-204. Review.

PMID:
9344252
40.

The alpha-subunit mRNAs for Gs and Go2 are differentially regulated by protein kinase A and protein kinase C in rat Sertoli cells.

Taskén KA, Jacobsen FW, Eikvar L, Hansson V, Haugen TB.

Biochim Biophys Acta. 1995 Feb 21;1260(3):269-75.

PMID:
7873600
41.

Reciprocal regulation of mRNA and protein for subunits of cAMP-dependent protein kinase (RI alpha and C alpha) by cAMP in a neoplastic B cell line (Reh).

Taskén K, Andersson KB, Skålhegg BS, Taskén KA, Hansson V, Jahnsen T, Blomhoff HK.

J Biol Chem. 1993 Nov 5;268(31):23483-9.

42.
43.

Half-lives of different sized mRNAs for the PKA subunit RI alpha are regulated differently in response to inhibition of transcription and translation.

Knutsen HK, Taskén KA, Eskild W, Jahnsen T, Hansson V.

Biochem Biophys Res Commun. 1992 Apr 15;184(1):454-60.

PMID:
1314594
44.

Inhibitors of RNA and protein synthesis stabilize messenger RNA for the RII beta subunit of protein kinase A in different cellular compartments.

Knutsen HK, Taskén KA, Eskild W, Hansson V.

Biochem Biophys Res Commun. 1992 Mar 16;183(2):632-9.

PMID:
1550570
47.

Different mechanisms are involved in cAMP-mediated induction of mRNAs for subunits of cAMP-dependent protein kinases.

Taskén KA, Knutsen HK, Attramadal H, Taskén K, Jahnsen T, Hansson V, Eskild W.

Mol Endocrinol. 1991 Jan;5(1):21-8.

PMID:
1850108

Supplemental Content

Loading ...
Support Center